Mobile

A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥67 years) previo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-002881-36

A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥67 years) previously vaccinated in the FluAS25-014 clinical trial with the same candidate vaccine. Fluarix™ (known as α-Rix® in Belgium) will be used as reference

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and reactogenicity of repeated vaccination with FluAS25, during 21 days following the intramuscular administration of the vaccine. Fluarix™ will be used as reference.

Critère d'inclusion

  • Immunization against influenza in male and female subjects aged 67 years and older

Liens